Daraxonrasib Doubles Survival in PDAC Without Matched Precedent to Anchor Value

Revolution Medicines' Rasonque Shows Near Doubling of OS in Pancreatic Cancer

Revolution Medicines announced compelling Phase III data from its RASolute 302 trial for the daily oral RAS(ON) inhibitor Rasonque (daraxonrasib) in pancreatic cancer patients. Presented at the 2026 European Society for Medical Oncology (ESMO) Congress, the results showed a near doubling of median overall survival (OS) to 13.2 months in the investigational arm compared to 6.7 months in the standard-of-care arm. This follows the drug's FDA approval in August 2026, offering significant hope in a historically challenging disease area.

• The Phase III RASolute 302 trial demonstrated a substantial improvement in overall survival, with patients receiving Rasonque achieving a median OS of 13.2 months, nearly double the 6.7 months observed in the standard-of-care arm. This outcome underscores Rasonque's potential to transform treatment for pancreatic cancer, a disease known for its poor prognosis.
• Further analysis presented at ESMO 2026 revealed Rasonque's efficacy across key tumor mutational subgroups. For patients with the common RAS G12D mutation, the overall response rate (ORR) was 32% with Rasonque versus 11% in the placebo cohort. Similarly, in RAS G12V patients, ORR was 24% compared to 9% with placebo, indicating broad activity.
• Rasonque's clinical success is complemented by its prior regulatory achievement, having received US Food and Drug Administration (FDA) approval in August 2026. The drug is administered as a daily oral RAS(ON) inhibitor, providing a convenient and effective therapeutic option for patients battling advanced pancreatic cancer.

The Enduring Challenge of Pancreatic Cancer Treatment

Pancreatic cancer remains one of the deadliest cancers due to difficulty in early diagnosis and its high resistance to chemotherapy and radiation. Pancreatic ductal adenocarcinoma (PDAC) is driven by nearly ubiquitous oncogenic drivers and a therapy-resistant tumor microenvironment (TME), while clinical outcomes are further shaped by metabolic disease, chronic inflammation, and microbiome dysregulation.

• Late presentation and limited resectability: Only 15-20% of patients with pancreatic ductal adenocarcinoma (PDAC) have a resectable tumor at the time of diagnosis. Main criteria for "unresectability" were infiltration of the celiac axis or superior mesenteric artery, and complete surgical resection is almost certainly unachievable in borderline resectable disease without multimodality treatment. Even patients with potentially resectable disease require multimodality treatment including chemotherapy and/or radiation to improve resectability and reduce recurrence, with ongoing need for refining preoperative staging to identify optimal surgical candidates.

• Desmoplastic stroma as a physical and metabolic barrier to drug delivery: Dense desmoplastic stroma comprises up to 80% of the tumor mass, with Type I collagen as the major component of the extracellular matrix and hyaluronan (HA) contributing to compression of vasculature, hypovascularity, impaired drug delivery and poor prognosis. Stromal depletion approaches have failed to show clinical responses in patients, and fibroblast drug scavenging may contribute to the clinical failure of gemcitabine in desmoplastic PDAC, with significantly increased concentrations of activated 2',2'-difluorodeoxycytidine-5'-triphosphate (dFdCTP) detected in pancreatic stellate cells (PSCs) and cancer-associated fibroblasts (CAFs) and low expression of hydrolytic cytosolic 5'-nucleotidases (Nt5c1A, Nt5c3).

• Inconclusive evidence for treatment sequencing and limited survival gains: Although at present no studies have been done to directly compare the benefit of neoadjuvant versus adjuvant approaches, randomized trials of neoadjuvant chemotherapy have failed to provide proof-of-concept outcomes, mostly because of failure to achieve recruitment targets. Neoadjuvant multimodal therapy could achieve a resection rate in the order of 60% of patients with locally advanced PDAC in a large single-arm cohort study, but for primarily resectable tumor study results remain unconvincing and neoadjuvant therapy should not be used routinely outside of a clinical trial. Adjuvant chemotherapy with gemcitabine and capecitabine in unselected patients can double 5-year overall survival to around 30% compared to mono-chemotherapy with either 5-fluorouracil with folinic acid or gemcitabine, while in selected patients adjuvant modified FOLFIRINOX can produce a 5-year survival rate of around 50%.

• Tumor heterogeneity, undruggable drivers and narrow biomarker-defined benefit: Oncogenic drivers such as KRAS, TP53, CDKN2A, and SMAD4 are nearly ubiquitous, with Kirsten rat sarcoma viral oncogene homolog mutations present in up to 90% of cases, though most variants remain undruggable and inhibitors against kinase effectors showed disappointing clinical activity. Breast cancer susceptibility gene 1/2 mutations occur in 4%-7% of patients, and other rare but actionable alterations such as v-raf murine sarcoma viral oncogene homolog B1 (V600), neurotrophic tyrosine receptor kinase, fibroblast growth factor receptor 2, and RET fusions show benefit in tumor-agnostic trials. High tumor mutational burden and mismatch repair deficiency are uncommon in PDAC, and regulatory approvals including immune checkpoint inhibitors for mismatch repair-deficient tumors, PARP inhibitors for BRCA1/2-mutant disease, and combination cytotoxic regimens such as NALIRIFOX in the metastatic setting benefit only a minority of patients.

• Immunosuppressive microenvironment and treatment delivery constraints: PDAC is characterized by a profoundly immunosuppressive tumor microenvironment and remains largely refractory to immunotherapy, with accumulation of suppressive regulatory B-cells, paradoxical complement activation favoring immunosuppression and broad class switching skewed toward inhibitory immunoglobulin subclasses, while therapies broadly targeting B-cells have failed in clinical trial. Tumour-related B7-H3 expression was significantly more intense in cases with lymph node metastasis and advanced pathological stage. High rates of distant failure underscore the importance of systemic therapy, yet thoracolumbar mean dose, maximum dose, V5, and V10 correlated with hematologic toxicity during and post concurrent chemoradiation (CRT) with gemcitabine, and composite frailty defined as modified frailty index [mFI] ≥2 and prognostic nutritional index [PNI]<45 was associated with reduced relative dose intensity (RDI <75%) with odds ratio [OR] 2.65, 95% confidence interval [CI] 1.02-7.16.

Rasonque: A Precision Approach for RAS-Mutant Pancreatic Cancer

Trials of daraxonrasib (RMC-6236) have selected patients with previously treated metastatic pancreatic ductal adenocarcinoma harboring oncogenic RAS mutations. The randomized phase III RASolute 302 trial compared daraxonrasib with chemotherapy in previously treated metastatic disease with oncogenic RAS mutations, building on a phase 1/2 clinical trial evaluating daraxonrasib monotherapy at clinically active dose levels in patients with previously treated, RAS mutant metastatic pancreatic adenocarcinoma. As of June 2026, the utility of daraxonrasib is limited to metastatic PDAC as a second-line agent in patients who failed or were intolerant of first-line chemotherapy.

Molecular profiling strategies studied alongside treatment include targeted sequencing of over 800 genes in paired pretreatment and end of treatment circulating tumor DNA samples from 44 patients in the phase 1/2 clinical trial, with treatment-emergent genomic alterations in the RAS signaling pathway observed in more than half (26 of 44; 59%) of these patients. Tissue and circulating tumor DNA profiling may support patient selection, monitoring of clonal evolution, and characterization of acquired resistance. Molecular profiling, next-generation sequencing, patient-derived organoids, and circulating tumor DNA may further improve treatment selection and monitoring.

Allele-level selection and modeling have also been explored, comparing resistance mechanisms between KRAS G12D and KRAS G12R, alleles with fundamentally different RAS network dynamics. In a KRAS G12R PDAC patient who progressed after 10 months on daraxonrasib, intratumoral EGFR/RASWT activation was shown, and rapid 3D-bioprinted patient-derived toroid modeling predicted sensitivity to trametinib-based combination therapy.

Pioneering New Combinations in Pancreatic Cancer Treatment

Immune checkpoint-based combinations represent a major investigational direction in pancreatic cancer, driven by the limited activity of PD-1/PD-L1 blockade alone. In a murine syngeneic model of metastatic pancreatic ductal adenocarcinoma (PDAC), an anti-CD137 agonist antibody (αCD137) most significantly improved survival when added to GVAX cancer vaccine and an anti-PD-1 antagonist antibody (αPD-1), with αPD-1 and αCD137 together increasing expression of costimulatory molecules CD137 and OX40 on CD4+PD-1+ and CD8+PD-1+ T cells and increasing expression of IFNγ in EOMES + exhausted tumor-infiltrating T cells. In a real-world study in Chinese cohort of 43 patients with advanced pancreatic cancer treated with PD-1/PD-L1 inhibitors from 2015-2017 as monotherapy or in combination with chemotherapy, targeted therapy, and CTLA-4 inhibitors, the objective response rate was 10.5%, the disease control rate was 50%, the median progression-free survival was 2.3 months, and the median overall survival (mOS) was 5.1 months, with mOS longer for combined therapy than monotherapy (5.4 vs 2.0 months, P = 0.020). A systematic review of seven studies of gemcitabine and nab-paclitaxel with immune checkpoint inhibitors (ICIs) reported median overall survival of ~15 months (range: 9.8-16.7) versus 8-9 months for chemotherapy alone, progression-free survival of 5.5-9 versus 3.5-5.5 months, and objective response rates of 18%-50% for combination therapy versus 23%-29% for chemotherapy, with ICIs including PD-1 inhibitors (pembrolizumab, nivolumab, toripalimab, camrelizumab, tislelizumab, sintilimab), PD-L1 inhibitor (durvalumab), and CTLA-4 inhibitor (tremelimumab). Additional vaccine-ICI strategies include a novel therapeutic MUC1-Vax vaccine containing PD-L1 that inhibited tumor growth in LLC and Panc02 tumor cells expressing high MUC1 and PD-L1 level and prolonged survival of cancer-bearing animals, and a Phase Ib study combining personalized autologous dendritic cell vaccine loaded with personalized neoantigen peptides (PEP-DC), aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma.

PARP inhibition combined with immunotherapy is being evaluated as maintenance therapy, particularly in homologous recombination deficiency (HRD). A case report described metastatic pancreatic cancer harboring a germline BRCA2 mutation treated with gemcitabine and albumin-bound paclitaxel chemotherapy from March 15, 2017 to June 30, 2017, and Nivolumab immunotherapy as maintenance therapy, followed by Olaparib orally administered from August 17, 2017 to March, achieving good progression-free survival (7.4 months) with the lesion classified as partial disease. The phase 2 POLAR trial (ClinicalTrials.gov identifier: NCT04666740) evaluated maintenance pembrolizumab plus olaparib following platinum-based chemotherapy in 63 participants stratified into cohort A (BRCA1/BRCA2-mutated or PALB2-mutated HRD, n = 33), cohort B (non-core HRD, n = 15) and cohort C (platinum sensitive, HRD-wild type, n = 15). Among RECIST-evaluable participants in cohort A (n = 20), ORR was 35% (95% confidence interval (CI): 15-59%), whereas 6-month PFS rate in the full cohort (n = 33) was 64% (95% CI: 49-82%), with median PFS and overall survival (OS) for cohort A of 8.3 (95% CI: 5.3-not reached (NR)) and 28 (95% CI: 12-NR) months, 2-year and 3-year OS rates of 56% (95% CI: 41-76%) and 44% (95% CI: 28-69%), respectively, at median follow-up of 37 months (95% CI: 27-47). In cohorts B and C, ORR was 8% (95% CI: 0-38%) and 14% (95% CI: 2%-43%); median PFS was 4.8 (95% CI: 4.0-12) and 3.3 (95% CI: 1.9-4.8) months; and median OS was 18 (95% CI: 13-NR) and 10 (95% CI: 8.9-24) months, respectively, with circulating tumor DNA response, increased tumor-infiltrating lymphocytes and enrichment of frameshift indel neoantigens associated with durable clinical benefit.

Cytotoxic combinations and sequencing strategies, including neoadjuvant and perioperative approaches, continue to define standards for advanced, borderline resectable and resectable disease. Polychemotherapy regimens including PEFG-PEXG-PDXG and GTX, FOLFIRINOX, and nanoparticle albumin-bound paclitaxel (nab-Paclitaxel) plus gemcitabine have shown survival advantage over single-agent gemcitabine, with FOLFIRINOX restricted to young and fit patients in PRODIGE 4/ACCORD 11. A retrospective cohort of 225 patients with locally advanced or metastatic pancreatic cancer reported median PFS of 7.3 months and median OS of 10.3 months for first-line FOLFIRINOX, with partial response in 50% and stable disease in 18%, and median PFS of 3.5 months for second-line gemcitabine/nab-paclitaxel with partial response in 21% and stable disease in 25%. Neoadjuvant comparisons include PREOPANC-2 comparing 8 cycles of neoadjuvant FOLFIRINOX followed by surgery without adjuvant treatment versus 3 cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36 Gy in 15 fractions) followed by surgery and 4 cycles of adjuvant gemcitabine; NORPACT-1 in resectable pancreatic head cancer reporting 18-month survival of 60% (95% CI 49-71) for neoadjuvant FOLFIRINOX versus 73% (62-84) for upfront surgery with median overall survival of 25·1 months (95% CI 17·2-34·9) versus 38·5 months (27·6-not reached); ESPAC5 in borderline resectable disease reporting 1-year overall survival of 39% (95% CI 24-61) for immediate surgery, 78% (60-100) for gemcitabine plus capecitabine, 84% (70-100) for FOLFIRINOX, and 60% (37-97) for capecitabine-based chemoradiation; a randomized phase 3 trial (NCT03750669) of neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX versus upfront surgery reporting median event-free survival of 15.3 months (95% CI, 12.6-19.3) versus 10.9 months (95% CI, 9.1-13.5; HR, 0.71; 95% CI, 0.54-0.93; p = 0.0136) and median overall survival of 35.4 months versus 27.2 months (HR, 0.73; 95% CI, 0.53-1.00); NEPAFOX comparing upfront surgery plus adjuvant gemcitabine versus perioperative FOLFIRINOX; and LAP07 reporting median overall survival of 16.5 months (95% CI, 14.5-18.5 months) for chemotherapy versus 15.2 months (95% CI, 13.9-17.3 months; HR, 1.03; 95% CI, 0.79-1.34; P = .83) for chemoradiotherapy (54 Gy plus capecitabine) after gemcitabine-based induction, and 13.6 months (95% CI, 12.3-15.3 months) for gemcitabine versus 11.9 months (95% CI, 10.4-13.5 months) for gemcitabine plus erlotinib (HR, 1.19; 95% CI, 0.97-1.45; P = .09).

Rasonque's Breakthrough Redefines Pancreatic Cancer Treatment

The recent announcement of Rasonque's (daraxonrasib) Phase III success in pancreatic cancer marks a profound shift in the fight against one of the most aggressive and historically intractable malignancies. For decades, pancreatic ductal adenocarcinoma (PDAC) has defied effective treatment, with patients facing a grim prognosis and limited options, particularly after first-line failure. The near doubling of median overall survival to 13.2 months with daraxonrasib, a daily oral RAS(ON) inhibitor, represents a monumental leap forward, establishing a new standard of care for second-line metastatic PDAC. This achievement is not merely incremental; it offers tangible, life-extending hope where little existed before.

Daraxonrasib's mechanism as a pan-RAS(ON) inhibitor is particularly significant. By targeting the active state of RAS across various isoforms and mutations, it addresses the vast majority of PDAC tumors driven by oncogenic KRAS. This broad-spectrum approach overcomes the limitations of allele-specific inhibitors, which are effective only in a smaller subset of patients. Beyond direct tumor suppression, research indicates that pan-RAS inhibition can also favorably remodel the tumor microenvironment, increasing T-cell infiltration and reducing immunosuppressive cells, potentially enhancing the efficacy of future combination strategies.

However, the journey does not end with this approval. The literature consistently highlights the challenge of adaptive resistance, which is anticipated to limit the durability of response to RAS inhibitors. Mechanisms observed include mutant KRAS amplifications, reactivation of RTK/MAPK/PI3K pathways, and allele-specific routes such as EGFR/RASWT activation or cyclophilin A downregulation. Furthermore, while generally favorable compared to cytotoxic regimens, earlier trials reported Grade 3 or higher treatment-related adverse events in a notable proportion of patients, a factor that will require careful management in broader clinical practice.

The path forward will undoubtedly involve sophisticated combination therapies. Preclinical studies are already exploring synergistic approaches, including combining daraxonrasib with DNA damage response agents, RTK inhibitors, or even other allele-specific RAS inhibitors. Strategies like concurrent stereotactic body radiation therapy, XPO1 inhibition, or even recombinant methioninase are showing promise in enhancing efficacy and overcoming resistance. Ultimately, the success of this new era in PDAC treatment will hinge on a precision oncology paradigm, where comprehensive genomic sequencing guides the rational selection and sequencing of targeted agents, transforming PDAC from an untreatable death sentence into a manageable molecular entity.